1. Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France. (3rd May 2020) Authors: Marine, Sivignon; Stéphane, Roze; Nicolas, Plommet; Felizzi, Federico; Paracha, Noman; Benjamin, Mazaleyrat; Perol, Maurice Journal: Journal of medical economics Issue: Volume 23:Number 5(2020) Page Start: 464 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗